基本數據
| LEI | 549300GFTTTXX5728360 |
| CIK | 1641631 |
SEC Filings
All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis.
These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to KokiCare, Inc.
SEC Filings (Chronological Order)
本頁面提供了一個完整的、按時間順序排列的美國證券交易委員會（SEC）申報文件列表，不包括我們在其他地方提供的所有權申報。
| June 1, 2026 |
Beyond Air Receives Nasdaq Hearing Panel Decision Granting Continued Listing Exhibit 99.1 Beyond Air Receives Nasdaq Hearing Panel Decision Granting Continued Listing GARDEN CITY, N.Y., June 1, 2026 (GLOBE NEWSWIRE) — Beyond Air, Inc. (NASDAQ: XAIR), a commercial-stage medical device and biopharmaceutical company focused on harnessing the power of nitric oxide (NO) to improve patients’ lives, today announced that the Nasdaq Hearings Panel (the “Panel”) has granted the Comp |
|
| June 1, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): May 28, 2026 Beyond Air, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-38892 47-3812456 (State or Other Jurisdiction of Incorporation) (Commission File Number) |
|
| May 5, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Definitive Proxy State |
|
| April 24, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☒ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Definitive Proxy State |
|
| April 15, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): April 13, 2026 Beyond Air, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-38892 47-3812456 (State or Other Jurisdiction of Incorporation) (Commission File Number |
|
| April 10, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): April 7, 2026 Beyond Air, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-38892 47-3812456 (State or Other Jurisdiction of Incorporation) (Commission File Number) |
|
| April 1, 2026 |
Exhibit 99.1 Beyond Air, Inc. Announces Resignation of Steve Lisi, CEO, and Appointment of Robert Goodman, Chief Commercial Officer, as CEO New Leadership to Accelerate Market Adoption and Scale Commercial Growth GARDEN CITY, N.Y., March 26, 2026 (GLOBE NEWSWIRE) — Beyond Air, Inc. (NASDAQ: XAIR) (“Beyond Air” or the “Company”), a commercial stage medical device and biopharmaceutical company focus |
|
| April 1, 2026 |
Separation and Release of Claims Agreement (NY over 40) Exhibit 10.1 Separation and Release of Claims Agreement (NY over 40) This Separation and Release of Claims Agreement (“Agreement”) is entered into by and between Beyond Air, Inc. (f/k/a AIT THERAPEUTICS INC. (the “Employer” or “Beyond Air”), on behalf of itself, its parent, subsidiaries, and other corporate affiliates, and each of their respective present and former employees, officers, directors, |
|
| April 1, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): March 26, 2026 Beyond Air, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-38892 47-3812456 (State or Other Jurisdiction of Incorporation) (Commission File Number |
|
| February 13, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): February 13, 2026 Beyond Air, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-38892 47-3812456 (State or Other Jurisdiction of Incorporation) (Commission File Num |
|
| February 13, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended December 31, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38892 BEYOND AIR, INC. |
|
| February 13, 2026 |
Exhibit 99.1 Beyond Air® Reports Fiscal Third Quarter 2026 Financial Results and Provides Corporate Update Increased revenue by 105% year-over-year (YoY) to $2.2 million in fiscal Q3 Maintain fiscal year 2026 revenue guidance of $8-10 million $22.3 million pro forma cash, cash equivalents, restricted cash and marketable securities, including net proceeds from recent PIPE transaction, expected to p |
|
| February 10, 2026 |
Filed pursuant to Rule 424(b)(3) Registration No. 333-293075 PROSPECTUS 524,990 Shares of Common Stock; Up to 3,405,828 Shares of Common Stock Issuable Upon Exercise of Pre-Funded Warrants; and Up to 3,930,818 Shares of Common Stock Issuable Upon Exercise of Common Warrants This prospectus relates to the resale or other disposition from time to time by the selling stockholders identified herein (e |
|
| February 5, 2026 |
February 5, 2026 Steven Lisi Chairman and Chief Executive Officer Beyond Air, Inc. |
|
| February 5, 2026 |
BEYOND AIR, INC. 900 Stewart Avenue, Suite 301 Garden City, NY 11530 BEYOND AIR, INC. 900 Stewart Avenue, Suite 301 Garden City, NY 11530 February 5, 2026 VIA EDGAR Securities and Exchange Commission Division of Corporate Finance Office of Industrial Applications and Services 100 F. Street, N.E. Washington, D.C. 20549 Attention: Conlon Danberg Re: Beyond Air, Inc. Registration Statement on Form S-3 File No. 333-293075 Ladies and Gentleman: In accordance with Rule 4 |
|
| February 2, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): January 30, 2026 Beyond Air, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-38892 47-3812456 (State or Other Jurisdiction of Incorporation) (Commission File Numb |
|
| January 30, 2026 |
As filed with the Securities and Exchange Commission on January 30, 2026 As filed with the Securities and Exchange Commission on January 30, 2026 Registration No. |
|
| January 30, 2026 |
Exhibit 107 Calculation of Filing Fee Tables Form S-3 (Form Type) Beyond Air, Inc. |
|
| January 20, 2026 |
PRE-FUNDED COMMON STOCK PURCHASE WARRANT BEYOND AIR, INC. Exhibit 4.1 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTR |
|
| January 20, 2026 |
Exhibit 10.2 REGISTRATION RIGHTS AGREEMENT This Registration Rights Agreement (this “Agreement”) is made and entered into as of January [], 2026, between Beyond Air, Inc., a Delaware corporation (the “Company”), and each of the several purchasers signatory hereto (each such purchaser, a “Purchaser” and, collectively, the “Purchasers”). This Agreement is made pursuant to the Securities Purchase Agr |
|
| January 20, 2026 |
Exhibit 10.1 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”) is dated as of January 14, 2026, between Beyond Air, Inc., a Delaware corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively the “Purchasers”). WHEREAS, subject to the terms and conditions set |
|
| January 20, 2026 |
Beyond Air Announces $5.0 Million Private Placement Priced At-the-Market Under Nasdaq Rules Exhibit 99.1 Beyond Air Announces $5.0 Million Private Placement Priced At-the-Market Under Nasdaq Rules Beyond Air™ GARDEN CITY, N.Y., Jan. 14, 2026 (GLOBE NEWSWIRE) — Beyond Air, Inc. (NASDAQ: XAIR) (“Beyond Air” or the “Company”), a commercial stage medical device and biopharmaceutical company focused on harnessing the power of nitric oxide to improve the lives of patients, today announced that |
|
| January 20, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): January 14, 2026 Beyond Air, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-38892 47-3812456 (State or Other Jurisdiction of Incorporation) (Commission File Numb |
|
| January 20, 2026 |
COMMON STOCK PURCHASE WARRANT BEYOND AIR, INC. Exhibit 4.2 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTR |
|
| January 20, 2026 |
Exhibit 10.3 PLACEMENT AGENCY AGREEMENT January 14, 2026 Rodman & Renshaw LLC 600 Lexington Avenue, 32nd Floor New York, NY 10022 Ladies and Gentlemen: Introduction. Subject to the terms and conditions herein (this “Agreement”), Beyond Air, Inc., a Delaware corporation (the “Company”), hereby agrees to sell up to an aggregate of $5,000,001 of securities of the Company, including, but not limited t |
|
| January 15, 2026 |
Exhibit 99.1 XTL Biopharmaceuticals Acquires 85% of Beyond Air’s Subsidiary NeuroNOS, Entering the Massive Autism Market with Nobel Prize-Winning Scientific Leadership Beyond Air™ Unmatched scientific firepower: Two Nobel Laureates join Founder Prof. Haitham Amal, leading global autism researcher Critical unmet need: 1 in 31 U.S. children now affected, zero FDA-approved disease-modifying therapies |
|
| January 15, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): December 8, 2025 Beyond Air, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-38892 47-3812456 (State or Other Jurisdiction of Incorporation) (Commission File Numb |
|
| December 30, 2025 |
Exhibit 10.1 EMPLOYMENT AGREEMENT EMPLOYMENT AGREEMENT (“Agreement”) is effective on December 25, 2025 between Beyond Air, Inc. (the “Company”), a Delaware Company, and Daniel Moorhead (the “Employee”), residing at 6832 Balsamroot Road, Larkspur, CO 80018. Recital: The parties desire to enter into this Agreement so as to provide for the employment of the Employee by the Company and for certain oth |
|
| December 30, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): December 26, 2025 Beyond Air, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-38892 47-3812456 (State or Other Jurisdiction of Incorporation) (Commission File Num |
|
| December 30, 2025 |
Beyond Air® Appoints Dan Moorhead as Chief Financial Officer Exhibit 99.1 Beyond Air® Appoints Dan Moorhead as Chief Financial Officer Garden City, NY, December 30, 2025 – Beyond Air, Inc. (NASDAQ: XAIR) (“Beyond Air” or the “Company”), a commercial stage medical device and biopharmaceutical company focused on harnessing the power of nitric oxide (NO) to improve the lives of patients, today announced the appointment of Dan Moorhead as Chief Financial Office |
|
| December 19, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Definitive Proxy State |
|
| December 16, 2025 |
PROSPECTUS 1,600,000 Shares of Common Stock Filed pursuant to rule 424(b)(3) Registration No. 333-291699 PROSPECTUS 1,600,000 Shares of Common Stock This prospectus relates to the offer and resale, from time to time, of up to 1,600,000 shares of common stock, par value $0.0001 per share, of Beyond Air, Inc., a Delaware corporation (“Beyond Air,” “we,” “us,” “our,” or the “Company”), held by Streeterville Capital, LLC, a Utah limited liabili |
|
| December 11, 2025 |
BEYOND AIR, INC. 900 Stewart Avenue, Suite 301 Garden City, NY 11530 BEYOND AIR, INC. 900 Stewart Avenue, Suite 301 Garden City, NY 11530 December 11, 2025 VIA EDGAR Securities and Exchange Commission Division of Corporate Finance 100 F. Street, N.E. Washington, D.C. 20549 Re: Beyond Air, Inc. Amendment No. 1 to the Registration Statement on Form S-1 Filed November 21, 2025 File No. 333-291699 Ladies and Gentlemen: In accordance with Rule 461 under the Securities A |
|
| December 11, 2025 |
As filed with the Securities and Exchange Commission on December 11, 2025 As filed with the Securities and Exchange Commission on December 11, 2025 Registration No. |
|
| December 11, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): December 8, 2025 Beyond Air, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-38892 47-3812456 (State or Other Jurisdiction of Incorporation) (Commission File Numb |
|
| November 28, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): November 21, 2025 Beyond Air, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-38892 47-3812456 (State or Other Jurisdiction of Incorporation) (Commission File Num |
|
| November 28, 2025 |
Beyond Air® Announces Transition of Chief Financial Officer Launched search for permanent successor Exhibit 99.1 Beyond Air® Announces Transition of Chief Financial Officer Launched search for permanent successor Garden City, NY, November 26, 2025 – Beyond Air, Inc. (NASDAQ: XAIR) (“Beyond Air” or the “Company”), a commercial stage medical device and biopharmaceutical company focused on harnessing the power of nitric oxide (NO) to improve the lives of patients, today announced that Doug Larson h |
|
| November 21, 2025 |
Exhibit 107 Calculation of Filing Fee Tables Form S-1 Beyond Air, Inc. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities Table 1: Newly Registered and Carry Forward Securities Security Type Security Class Title Fee Calculation Rule or Carry Forward Rule Amount Registered(1) Proposed Maximum Offering Price Per Share(2) Maximum Aggregate Offering Price Fee R |
|
| November 21, 2025 |
As filed with the Securities and Exchange Commission on November 21, 2025 As filed with the Securities and Exchange Commission on November 21, 2025 Registration No. |
|
| November 14, 2025 |
Exhibit 99.1 Beyond Air® Reports Fiscal Second Quarter 2026 Financial Results and Provides Corporate Update Increased revenue by 128% year over year (YoY) to $1.8 million Appointed Beyond Air Board member Bob Goodman as Interim Chief Commercial Officer Raised $12.0 million in debt financing; proforma cash, cash equivalents, restricted cash and marketable securities of $22.9 million as of September |
|
| November 14, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): November 10, 2025 Beyond Air, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-38892 47-3812456 (State or Other Jurisdiction of Incorporation) (Commission File Num |
|
| November 10, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38892 BEYOND AIR, INC. |
|
| November 5, 2025 |
INTELLECTUAL PROPERTY SECURITY AGREEMENT Exhibit 10.11 INTELLECTUAL PROPERTY SECURITY AGREEMENT This INTELLECTUAL PROPERTY SECURITY AGREEMENT (“IP Security Agreement”), dated as of November 4, 2025, is made by BEYOND AIR LTD, an Israeli business entity (“Guarantor”), in favor of STREETERVILLE CAPITAL, LLC, a Utah limited liability company (the “Secured Party”). A. Beyond Air, Inc., a Delaware limited liability company and parent company |
|
| November 5, 2025 |
AMENDED AND RESTATED LOAN AND SECURITY AGREEMENT Exhibit 10.3 AMENDED AND RESTATED LOAN AND SECURITY AGREEMENT This LOAN AND SECURITY AGREEMENT (“Agreement”) is entered into and effective as of November 3, 2025, among Beyond Air, Inc., a Delaware corporation (the “Borrower”) and, BCR8V LLC, a Delaware limited liability company (“Lender”)Lender. PRELIMINARY STATEMENTS Prior the date hereof Borrower and Lender entered into that certain Loan and Se |
|
| November 5, 2025 |
Exhibit 4.2 SECURED PROMISSORY NOTE Effective Date: November 4, 2025 U.S. $12,050,000.00 FOR VALUE RECEIVED, Beyond Air, Inc., a Delaware corporation (“Borrower”), promises to pay to Streeterville Capital, LLC, a Utah limited liability company, or its successors or assigns (“Lender”), $12,050,000.00 and any interest, fees, charges, and late fees accrued hereunder on the date that is twenty-four (2 |
|
| November 5, 2025 |
Exhibit 10.12 PLEDGE AGREEMENT This PLEDGE AGREEMENT (this “Agreement”) is entered into as of November 4, 2025 by and between Streeterville Capital, LLC, a Utah limited liability company (“Secured Party”), and Beyond Air, Inc., a Delaware corporation (“Pledgor”). A. Effective as of the date hereof, Secured Party purchased from Pledgor that certain Secured Promissory Note of even date herewith in t |
|
| November 5, 2025 |
Exhibit 10.5 Note Purchase Agreement This Note Purchase Agreement (this “Agreement”), dated as of November 4, 2025, is entered into by and between Beyond Air, Inc., a Delaware corporation (“Company”), and Streeterville Capital, LLC, a Utah limited liability company, its successors and/or assigns (“Investor”). A. Company and Investor are executing and delivering this Agreement in reliance upon an e |
|
| November 5, 2025 |
Exhibit 10.1 EQUITY PURCHASE AGREEMENT This Equity Purchase Agreement is entered into as of November 4, 2025 (this “Agreement”), by and between Beyond Air, Inc., a Delaware corporation (the “Company”), and Streeterville Capital, LLC, a Utah limited liability company (the “Investor”, and together with the Company, the “Parties”). WHEREAS, the Parties desire that, upon the terms and subject to the c |
|
| November 5, 2025 |
Beyond Air® Secures Up to $32 Million to Accelerate Growth Exhibit 99.1 Beyond Air® Secures Up to $32 Million to Accelerate Growth Beyond Air™ Enters agreements for a $12 million promissory note and a $20 million equity line of credit with Streeterville Capital Proforma cash, cash equivalents, restricted cash and marketable securities of $22.9 million as of September 30, 2025, including $12 million from the promissory note Extends cash runway into calenda |
|
| November 5, 2025 |
[Remainder of page intentionally left blank; signature page to follow] Exhibit 10.6 GUARANTY This GUARANTY, made effective as of November 4, 2025, is given by XAIR Holdings, LLC, a Utah limited liability company (“Guarantor”), for the benefit of Streeterville Capital, LLC, a Utah limited liability company, and its successors, transferees, and assigns (collectively “Investor”). PURPOSE A. Beyond Air, Inc., a Delaware corporation and parent of Guarantor (“Company”), ha |
|
| November 5, 2025 |
[signature page follows immediately] Exhibit 10.4 WAIVER This Waiver, dated as of November 3, 2025 (the “Waiver”), is made by BCR8V LLC, a Delaware limited liability company (“Lender”) in favor of Beyond Air, Inc., a Delaware corporation (“Borrower”, and together with Lender, the “Parties”, and each, a “Party”). WHEREAS, the Parties have entered into a Loan and Security Agreement dated as of November 1, 2024 but effective as of Octob |
|
| November 5, 2025 |
Exhibit 10.10 Security Agreement This Security Agreement (this “Agreement”), dated as of November 4, 2025, is executed by Beyond Air Ltd, an Israeli business entity (“Guarantor”), in favor of Streeterville Capital, LLC, a Utah limited liability company (“Secured Party”). A. Beyond Air, Inc., a Delaware corporation (“Debtor”), has issued to Secured Party a certain Secured Promissory Note of even da |
|
| November 5, 2025 |
[Remainder of page intentionally left blank] Exhibit 10.7 GUARANTY This GUARANTY, made effective as of November 4, 2025, is given by Beyond Air Australia Pty Ltd, an Australian company (“BA Australia”), Beyond Air Ireland Ltd, an Irish company (“BA Ireland”), and Beyond Air Ltd, an Israeli company (“BA Israel”), for the benefit of Streeterville Capital, LLC, a Utah limited liability company, and its successors, transferees, and assigns (“Inv |
|
| November 5, 2025 |
Exhibit 4.1 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR THE SECURITIES LAWS OF ANY STATE OF THE UNITED STATES OR IN ANY OTHER JURISDICTION. NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE MAY BE OFFERED, SOLD OR TRANSFERRED IN THE ABSENCE OF AN EFFECTIVE REGISTR |
|
| November 5, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): November 3, 2025 Beyond Air, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-38892 47-3812456 (State or Other Jurisdiction of Incorporation) (Commission File Numb |
|
| November 5, 2025 |
Exhibit 10.2 REGISTRATION RIGHTS AGREEMENT This REGISTRATION RIGHTS AGREEMENT (this “Agreement”), dated as of November 4, 2025, is entered into by and between BEYOND AIR, INC., a Delaware corporation (the “Company”), and STREETERVILLE CAPITAL, LLC, a Utah limited liability company (together with it permitted assigns, the “Investor”). Capitalized terms used herein and not otherwise defined herein s |
|
| November 5, 2025 |
Exhibit 10.8 Security Agreement This Security Agreement (this “Agreement”), dated as of November 4, 2025, is executed by Beyond Air, Inc., a Delaware corporation (“Debtor”), in favor of Streeterville Capital, LLC, a Utah limited liability company (“Secured Party”). A. Debtor has issued to Secured Party a certain Secured Promissory Note of even date herewith, as may be amended from time to time, in |
|
| November 5, 2025 |
INTELLECTUAL PROPERTY SECURITY AGREEMENT Exhibit 10.9 INTELLECTUAL PROPERTY SECURITY AGREEMENT This INTELLECTUAL PROPERTY SECURITY AGREEMENT (“IP Security Agreement”), dated as of November 4, 2025, is made by BEYOND AIR, INC., a Delaware corporation (“Debtor”), in favor of STREETERVILLE CAPITAL, LLC, a Utah limited liability company (the “Secured Party”). A. Debtor issued to Secured Party a certain Secured Promissory Note of even date he |
|
| September 30, 2025 |
September 30, 2025 Steven Lisi Chief Executive Officer Beyond Air, Inc. 900 Stewart Avenue, Suite 301 Garden City, NY 11530 Re: Beyond Air, Inc. Registration Statement on Form S-3 Filed September 25, 2025 File No. 333-290520 Dear Steven Lisi: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acc |
|
| September 30, 2025 |
Beyond Air, Inc. 900 Stewart Avenue, Suite 301 Garden City, NY 11530 (516) 665-8200 Beyond Air, Inc. 900 Stewart Avenue, Suite 301 Garden City, NY 11530 (516) 665-8200 September 30, 2025 VIA EDGAR Securities and Exchange Commission Division of Corporation Finance 100 F Street N.E. Washington, D.C. 20549 Re: Beyond Air, Inc. Registration Statement on Form S-3 File No. 333-290520 Ladies and Gentlemen: Beyond Air, Inc., hereby requests withdrawal of its request for the acceleration |
|
| September 30, 2025 |
As filed with the Securities and Exchange Commission on September 30, 2025 As filed with the Securities and Exchange Commission on September 30, 2025 Registration No. |
|
| September 30, 2025 |
Beyond Air, Inc. 900 Stewart Avenue, Suite 301 Garden City, NY 11530 (516) 665-8200 Beyond Air, Inc. 900 Stewart Avenue, Suite 301 Garden City, NY 11530 (516) 665-8200 September 30, 2025 VIA EDGAR Securities and Exchange Commission Division of Corporation Finance 100 F Street N.E. Washington, D.C. 20549 Re: Beyond Air, Inc. Registration Statement on Form S-3 File No. 333-290520 Ladies and Gentlemen: Pursuant to Rule 461 promulgated under the Securities Act, the undersigned respec |
|
| September 30, 2025 |
X0101 EFFECT 33 LIVE 2025-09-30 17:15:00 S-3 0001641631 Beyond Air, Inc. 333-290520 |
|
| September 30, 2025 |
Beyond Air, Inc. 900 Stewart Avenue, Suite 301 Garden City, NY 11530 (516) 665-8200 Beyond Air, Inc. 900 Stewart Avenue, Suite 301 Garden City, NY 11530 (516) 665-8200 September 30, 2025 VIA EDGAR Securities and Exchange Commission Division of Corporation Finance 100 F Street N.E. Washington, D.C. 20549 Re: Beyond Air, Inc. Registration Statement on Form S-3 File No. 333-290520 Ladies and Gentlemen: Pursuant to Rule 461 promulgated under the Securities Act, the undersigned respec |
|
| September 25, 2025 |
As filed with the Securities and Exchange Commission on September 25, 2025 As filed with the Securities and Exchange Commission on September 25, 2025 Registration No. |
|
| September 25, 2025 |
Exhibit 107 Calculation of Filing Fee Tables Form S-3 (Form Type) Beyond Air, Inc. |
|
| September 9, 2025 |
Beyond Air, Inc. WARRANT TO PURCHASE COMMON STOCK Exhibit 4.1 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR THE SECURITIES LAWS OF ANY STATE OF THE UNITED STATES OR IN ANY OTHER JURISDICTION. NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE MAY BE OFFERED, SOLD OR TRANSFERRED IN THE ABSENCE OF AN EFFECTIVE REGISTR |
|
| September 9, 2025 |
Beyond Air Announces Exercise of Warrants for $3.25 Million of Gross Proceeds Exhibit 99.1 Beyond Air Announces Exercise of Warrants for $3.25 Million of Gross Proceeds GARDEN CITY, N.Y., September 08, 2025 (GLOBE NEWSWIRE) – Beyond Air, Inc. (NASDAQ: XAIR) (“Beyond Air” or the “Company”), a commercial stage medical device and biopharmaceutical company focused on harnessing the power of nitric oxide (NO) to improve the lives of patients, today announced the entry into a def |
|
| September 9, 2025 |
73,765,634 Shares of Common Stock Filed pursuant to Rule 424(b)(3) Registration No. 333-282834 PROSPECTUS SUPPLEMENT (To Prospectus dated November 26, 2024) 73,765,634 Shares of Common Stock This prospectus supplement updates, amends and supplements the prospectus dated November 26, 2024 (the “Prospectus”), which forms a part of our Registration Statement on Form S-3 (Registration No. 333-282834). This prospectus supplement is bei |
|
| September 9, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): September 8, 2025 Beyond Air, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-38892 47-3812456 (State or Other Jurisdiction of Incorporation) (Commission File Num |
|
| September 9, 2025 |
Exhibit 10.1 Beyond Air, Inc. September 8, 2025 To the Holder whose name appears on the signature page attached hereto Re: Inducement Agreement to Exercise Warrant Dear Holder: Pursuant to this letter agreement (this “Agreement”), Beyond Air, Inc. (the “Company”) is pleased to offer to you (the “Holder”) the opportunity to exercise all of the common stock purchase warrant issued to you on Septembe |
|
| September 8, 2025 |
Exhibit 99.1 NeuroNOS Granted FDA Orphan Drug Designation for Glioblastoma, the Most Common and Deadliest Primary Malignant Brain Cancer in Adults BOSTON, 08-September-2025 (GLOBE NEWSWIRE) - NeuroNOS, a biopharmaceutical company focused on developing treatments for neurological disorders and neuro-oncology, and a subsidiary of Beyond Air (NASDAQ: XAIR), today announced that the U.S. Food and Drug |
|
| September 8, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): September 8, 2025 Beyond Air, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-38892 47-3812456 (State or Other Jurisdiction of Incorporation) (Commission File Num |
|
| August 18, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): August 12, 2025 Beyond Air, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-38892 47-3812456 (State or Other Jurisdiction of Incorporation) (Commission File Numbe |
|
| August 18, 2025 |
Exhibit 99.1 Beyond Air® Reports Fiscal First Quarter 2026 Financial Results and Provides Corporate Update August 12, 2025 Increased revenues by 157% to $1.8 million, compared with $0.7 million for the fiscal quarter ended June 30, 2024 Awarded a national group purchasing agreement for therapeutic gases by Premier, Inc., which has more than 4,350 member hospitals and health systems in its network |
|
| August 12, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38892 BEYOND AIR, INC. (Exa |
|
| July 10, 2025 |
Form of Certificate of Amendment Exhibit 3.1 THIRD CERTIFICATE OF AMENDMENT OF THE AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF BEYOND AIR, INC. Beyond Air, Inc. (the “Corporation”), a corporation organized and existing under the laws of the State of Delaware hereby certifies as follows: 1. The name of the Corporation is Beyond Air, Inc. The Corporation’s original Certificate of Incorporation was filed with the Secretary |
|
| July 10, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): July 9, 2025 Beyond Air, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-38892 47-3812456 (State or Other Jurisdiction of Incorporation) (Commission File Number) |
|
| June 25, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): June 20, 2025 Beyond Air, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-38892 47-3812456 (State or Other Jurisdiction of Incorporation) (Commission File Number) |
|
| June 20, 2025 |
List of subsidiaries of Beyond Air, Inc. Exhibit 21.1 Subsidiary Jurisdiction of Incorporation Beyond Air Ltd. Israel Beyond Air Ireland Limited Ireland Beyond Air Australia Pty. Ltd. Australia Beyond Cancer Bermuda Limited Bermuda Beyond Cancer U.S., Inc. Delaware NeuroNos Limited Ireland NeuroNos Israel Limited Israel XAIR Israel Ltd Israel Beyond Air Cyprus Limited Cyprus NeuroNos US Inc Delaware |
|
| June 20, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE FISCAL YEAR ENDED MARCH 31, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission file number: 001-38892 BEYOND AIR, INC. |
|
| June 20, 2025 |
Exhibit 97 Beyond Air, Inc. Incentive Compensation Recovery Policy Adopted by the Board of Directors (the “Board”) of Beyond Air, Inc. (the “Company”) on November 20, 2023 The Company is committed to conducting business in accordance with the highest ethical and legal standards, and the Board believes that a culture that emphasizes integrity and accountability is in the best interests of the Compa |
|
| June 18, 2025 |
Exhibit 99.2 Beyond Air Submits FDA PMA Supplement for Next Generation LungFit® PH LungFit PH II’s smaller, lightweight, transport-ready design is expected to open the entirety of the NO market Final design based upon substantial feedback from respiratory therapists across the country Garden City, NY, June 16, 2025 – Beyond Air, Inc. (NASDAQ: XAIR) (“Beyond Air” or the “Company”), a commercial sta |
|
| June 18, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): June 18, 2025 Beyond Air, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-38892 47-3812456 (State or Other Jurisdiction of Incorporation) (Commission File Number) |
|
| June 18, 2025 |
Exhibit 99.1 Beyond Air® Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update Revenues increased 220% to $3.7 million, compared with $1.2 million for the fiscal year ended March 31, 2024 Expect to report revenue of at least $1.7 million for quarter ending June 30, 2025, and introducing revenue guidance of $12-$16 million for the full fiscal year 2026 Submitted |
|
| May 5, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Definitive Proxy State |
|
| April 25, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☒ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Definitive Proxy State |
|
| March 28, 2025 |
Exhibit 99.1 NeuroNOS Secures $2.0 Million in Funding to Advance Development of an Innovative Autism Therapy First-in-human studies anticipated to begin in 2026 Engaged a top tier U.S. based contract manufacturer to ensure the highest standards of quality Currently in the advanced stages of formulation development for subcutaneous injection, with plans for an oral formulation BOSTON, March 24, 202 |
|
| March 28, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): March 24, 2025 Beyond Air, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-38892 47-3812456 (State or Other Jurisdiction of Incorporation) (Commission File Number |
|
| March 14, 2025 |
Exhibit 99.1 Beyond Air Announces Agreements Expanding Global Distribution of LungFit® PH Distribution agreements recently signed for France, Turkey, Romania and Morocco LungFit PH international distribution network now includes 18 countries Initial international orders for LungFit PH systems have been received for four countries GARDEN CITY, N.Y., March 11, 2025 (GLOBE NEWSWIRE) — Beyond Air, Inc |
|
| March 14, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): March 11, 2025 Beyond Air, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-38892 47-3812456 (State or Other Jurisdiction of Incorporation) (Commission File Number |
|
| February 14, 2025 |
Filed Pursuant to Rule 424(b)(5) Registration No. 333-284653 PROSPECTUS SUPPLEMENT (To Prospectus dated February 10, 2025) $9,892,518 Beyond Air, Inc. Common Stock We have entered into a sales agreement with BTIG, LLC, or BTIG, who we refer to as the agent, relating to shares of our common stock offered by this prospectus supplement. In accordance with the terms of the sales agreement, we may offe |
|
| February 14, 2025 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 14, 2025 Beyond Air, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38892 47-3812456 (State or other jurisdiction of incorporation) (Commission File |
|
| February 14, 2025 |
Results of Operations and Financial Condition, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): February 10, 2025 Beyond Air, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-38892 47-3812456 (State or Other Jurisdiction of Incorporation) (Commission File Num |
|
| February 14, 2025 |
Exhibit 99.1 Beyond Air® Reports Fiscal Third Quarter 2025 Financial Results and Provides Corporate Update Revenues increased 34% compared to the previous quarter ended September 30, 2024; and exceeded $1 million Received CE Mark for LungFit PH® in Europe and Market Authorization in Australia; international shipments to commence later this year Conference call at 4:30 p.m. ET today, February 10th |
|
| February 14, 2025 |
At-The-Market Equity Offering Sales Agreement, dated as of February 14, 2025 Exhibit 1.1 Beyond Air, Inc. Up to $35,000,000 COMMON STOCK AT-THE-MARKET SALES AGREEMENT February 14, 2025 BTIG, LLC 65 East 55th Street New York, New York 10022 Ladies and Gentlemen: Beyond Air, Inc., a Delaware corporation (the “Company”), and BTIG, LLC (the “Agent”), as sales agent, confirm their agreement (this “Agreement”) as follows: 1. Issuance and Sale of Shares. The Company agrees that, |
|
| February 10, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended December 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38892 BEYOND AIR, INC. |
|
| February 6, 2025 |
February 6, 2025 Steven Lisi Chairman and Chief Executive Officer Beyond Air, Inc. |
|
| February 6, 2025 |
BEYOND AIR, INC. 900 Stewart Avenue, Suite 301 Garden City, NY 11530 BEYOND AIR, INC. 900 Stewart Avenue, Suite 301 Garden City, NY 11530 February 6, 2025 VIA EDGAR Securities and Exchange Commission Division of Corporate Finance 100 F. Street, N.E. Washington, D.C. 20549 Re: Beyond Air, Inc. Registration Statement on Form S-3 Filed January 31, 2025 File No. 333-284653 Ladies and Gentlemen: In accordance with Rule 461 under the Securities Act of 1933, as amended, t |
|
| February 5, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): February 5, 2025 Beyond Air, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-38892 47-3812456 (State or Other Jurisdiction of Incorporation) (Commission File Numb |
|
| February 5, 2025 |
Beyond Air® Granted 180-Day Extension by Nasdaq to Regain Compliance with Minimum Bid Requirement Exhibit 99.1 Beyond Air® Granted 180-Day Extension by Nasdaq to Regain Compliance with Minimum Bid Requirement Garden City, NY, February 5, 2025 – Beyond Air, Inc. (NASDAQ: XAIR) (“Beyond Air” or the “Company”), a commercial stage medical device and biopharmaceutical company focused on harnessing the power of nitric oxide (NO) to improve the lives of patients, today announced it received a notific |
|
| January 31, 2025 |
Filing Fee Table (filed herewith). Exhibit 107 Calculation of Filing Fee Tables Form S-3 (Form Type) Beyond Air, Inc. |
|
| January 31, 2025 |
As filed with the Securities and Exchange Commission on January 31, 2025 As filed with the Securities and Exchange Commission on January 31, 2025 Registration No. |
|
| January 31, 2025 |
Form of Indenture (filed herewith). Exhibit 4.4 BEYOND AIR, INC. and as Trustee INDENTURE Dated as of ARTICLE 1 DEFINITIONS AND INCORPORATION BY REFERENCE 1 1.1 Definitions 1 1.2 Other Definitions 4 1.3 Incorporation by Reference of Trust Indenture Act 4 1.4 Rules of Construction 5 ARTICLE 2 THE SECURITIES 5 2.1 Issuable in Series 5 2.2 Establishment of Terms of Series of Securities 5 2.3 Execution and Authentication 7 2.4 Registrar |
|
| December 20, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): December 17, 2024 Beyond Air, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-38892 47-3812456 (State or Other Jurisdiction of Incorporation) (Commission File Num |
|
| December 20, 2024 |
Letter from Marcum LLP to the Securities and Exchange Commission, dated December 20, 2024. Exhibit 16.1 December 20, 2024 Securities and Exchange Commission 100 F Street, N.E. Washington, DC 20549 Commissioners: We have read the statements made by Beyond Air, Inc. under Item 4.01 of its Form 8-K dated December 17, 2024. We agree with the statements concerning our Firm in such Form 8-K; we are not in a position to agree or disagree with other statements of Beyond Air, Inc. contained ther |
|
| December 13, 2024 |
Form of Stock Option Agreement (Inducement Grant). Exhibit 10.2 Stock Option Inducement Agreement This Stock Option Inducement Agreement (this “Agreement”) is made and entered into as of [DATE] by and between BEYOND AIR, INC., a Delaware corporation (the “Company”) and [NAME] (the “Participant”). Grant Date: Exercise Price per Share: Number of Option Shares: Expiration Date: 1. Grant of Option. 1.1 Grant; Type of Option. The Company desires to emp |
|
| December 13, 2024 |
Exhibit 107 Calculation of Filing Fee Table Form S-8 (Form Type) Beyond Air, Inc. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered(1) Proposed Maximum Offering Price Per Unit Proposed Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Equity Common Stock, par value |
|
| December 13, 2024 |
As filed with the Securities and Exchange Commission on December 13, 2024 As filed with the Securities and Exchange Commission on December 13, 2024 Registration No. |
|
| December 13, 2024 |
Beyond Air, Inc. Seventh Amended and Restated 2013 Equity Incentive Plan. Exhibit 10.1 BEYOND AIR, INC. Seventh AMENDED AND RESTATED 2013 EQUITY INCENTIVE PLAN (effective November 22, 2024, subject to stockholder approval) 1. Purpose; Eligibility. 1.1 General Purpose. This Beyond Air, Inc. Seventh Amended and Restated 2013 Equity Incentive Plan (the “Plan”) is hereby established by Beyond Air, Inc., a Delaware corporation (the “Company”), which amends and restates the S |
|
| December 6, 2024 |
Other Events, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): December 3, 2024 Beyond Air, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-38892 47-3812456 (State or Other Jurisdiction of Incorporation) (Commission File Numb |
|
| December 6, 2024 |
Exhibit 99.1 Beyond Cancer Announces Approval by the Israeli Ministry of Health to Conduct a Phase 1b Clinical Trial Utilizing Low Volume Ultra-High Concentration Nitric Oxide (LV UNO) in Combination with Anti-PD-1 Therapy - The Phase 1b study will evaluate LV UNO in unresectable cutaneous or subcutaneous histologically confirmed primary or metastatic solid tumor cancer patients that have progress |
|
| December 3, 2024 |
Exhibit 99.1 Beyond Air Receives CE Mark in Europe for the LungFit® PH System Indication covers newborn infants with hypoxic respiratory failure and peri- and post-operative pulmonary hypertension to improve right ventricular function in conjunction with heart surgery A $1 million milestone payment is triggered from Asia-Pacific partner, Getz Healthcare Garden City, NY, December 2, 2024 – Beyond A |
|
| December 3, 2024 |
Other Events, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): December 2, 2024 Beyond Air, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-38892 47-3812456 (State or Other Jurisdiction of Incorporation) (Commission File Numb |
|
| November 26, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): November 22, 2024 Beyond Air, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-38892 47-3812456 (State or Other Jurisdiction of Incorporation) (Commission File Num |
|
| November 26, 2024 |
73,765,634 Shares of Common Stock Filed pursuant to Rule 424(b)(3) Registration No. 333-282834 PROSPECTUS 73,765,634 Shares of Common Stock The selling stockholders named in this prospectus may use this prospectus to offer and resell from time to time up to an aggregate of 73,765,634 shares of our common stock, par value $0.0001 per share, which are comprised of (i) 22,046,747 shares of common stock issued and outstanding (“common |
|
| November 26, 2024 |
Exhibit 3.1 SECOND CERTIFICATE OF AMENDMENT SECOND CERTIFICATE OF AMENDMENT OF THE AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF BEYOND AIR, INC. Beyond Air, Inc. (the “Corporation”), a corporation organized and existing under the laws of the State of Delaware hereby certifies as follows: 1. The name of the Corporation is Beyond Air, Inc. The Corporation’s original Certificate of Incorporat |
|
| November 22, 2024 |
BEYOND AIR, INC. 900 Stewart Avenue, Suite 301 Garden City, NY 11530 BEYOND AIR, INC. 900 Stewart Avenue, Suite 301 Garden City, NY 11530 November 22, 2024 VIA EDGAR Securities and Exchange Commission Division of Corporate Finance 100 F. Street, N.E. Washington, D.C. 20549 Attention: Juan Grana and Katherine Bagley Re: Beyond Air, Inc. Registration Statement on Form S-3 File No. 333-282834 Ladies and Gentlemen: In accordance with Rule 461 under the Securities Act o |
|
| November 21, 2024 |
As filed with the Securities and Exchange Commission on November 21, 2024 As filed with the Securities and Exchange Commission on November 21, 2024 Registration Statement No. |
|
| November 21, 2024 |
Filing Fee Table (filed herewith). Exhibit 107 Calculation of Filing Fee Tables Form S-3 (Form Type) Beyond Air, Inc. |
|
| November 18, 2024 |
Results of Operations and Financial Condition, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): November 11, 2024 Beyond Air, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-38892 47-3812456 (State or Other Jurisdiction of Incorporation) (Commission File Num |
|
| November 18, 2024 |
Exhibit 99.1 Beyond Air® Reports Fiscal Second Quarter 2025 Financial Results and Provides Corporate Update Revenues increased 17% compared to the previous quarter ended June 30, 2024 Strengthened balance sheet is expected to provide sufficient cash runway through June 2026 Completed a $20.6 million private placement offering with multiple healthcare-focused institutional funds and Company insider |
|
| November 12, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38892 BEYOND AIR, INC. |
|
| November 8, 2024 |
November 8, 2024 VIA EDGAR Juan Grana and Katherine Bagley Division of Corporation Finance Office of Industrial Applications and Services Securities and Exchange Commission 100 F Street, NE Washington, D. |
|
| November 6, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): November 1, 2024 Beyond Air, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-38892 47-3812456 (State or Other Jurisdiction of Incorporation) (Commission File Numb |
|
| November 6, 2024 |
Exhibit 4.1 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR THE SECURITIES LAWS OF ANY STATE OF THE UNITED STATES OR IN ANY OTHER JURISDICTION. NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE MAY BE OFFERED, SOLD OR TRANSFERRED IN THE ABSENCE OF AN EFFECTIVE REGISTR |
|
| November 6, 2024 |
Exhibit 10.1 LOAN AND SECURITY AGREEMENT This LOAN AND SECURITY AGREEMENT (“Agreement”) is entered into as of November 1, 2024 but effective as of October 4, 2024, among Beyond Air, Inc., a Delaware corporation (the “Borrower”), BCR8V LLC, a Delaware limited liability company (“Lender”). PRELIMINARY STATEMENTS The Borrower has requested that Lender extend a $11,500,000 term loan to the Borrower. L |
|
| November 4, 2024 |
November 4, 2024 Steven Lisi Chief Executive Officer Beyond Air, Inc. 900 Stewart Avenue, Suite 301 Garden City, NY 11530 Re: Beyond Air, Inc. Registration Statement on Form S-3 Filed October 25, 2024 File No. 333-282834 Dear Steven Lisi: We have conducted a limited review of your registration statement and have the following comment. Please respond to this letter by amending your registration sta |
|
| October 31, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Definitive Proxy State |
|
| October 25, 2024 |
As filed with the Securities and Exchange Commission on October 25, 2024 As filed with the Securities and Exchange Commission on October 25, 2024 Registration Statement No. |
|
| October 25, 2024 |
Exhibit 107 Calculation of Filing Fee Tables Form S-3 (Form Type) Beyond Air, Inc. |
|
| October 18, 2024 |
900 STEWART AVENUE, Suite 301 Garden City, NY 11530 NOTICE OF ANNUAL MEETING OF STOCKHOLDERS To Be Held at 4:30 p. |
|
| October 9, 2024 |
Joint Filing Agreement dated October 3, 2024. EX-99.2 2 beyondairex99-2.htm EXHIBIT 99.2 Exhibit 99.2 AGREEMENT JOINT FILING OF SCHEDULE 13G Each of the undersigned hereby agrees to file jointly the Schedule 13G to which this Agreement is attached, and any amendments to the Schedule 13G (the “Schedule 13G”) filed with respect to the common stock, par value $0.0001 per share, of Beyond Air, Inc., which may be deemed necessary, pursuant to Regu |
|
| October 9, 2024 |
Shareholder Director Nominations UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): October 9, 2024 Beyond Air, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-38892 47-3812456 (State or Other Jurisdiction of Incorporation) (Commission File Numbe |
|
| October 9, 2024 |
XAIR / Beyond Air, Inc. / Avenue Venture Opportunities Fund, L.P. - SC 13G/A Passive Investment SC 13G/A 1 beyondairsc13ga.htm SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Act of 1934 (Amendment No. 1)* BEYOND AIR, INC. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 08862L103 (CUSIP Number) October 4, 2024 (Date of Event Which Requires Filing of this Statement) Check the appropria |
|
| October 3, 2024 |
Power of Attorney dated January 28, 2019. EX-99.1 2 beyondairex99-1.htm EXHIBIT 99.1 Exhibit 99.1 POWER OF ATTORNEY This Power of Attorney is being granted in connection with executing regulatory filings and related documents. Marc Lasry hereby constitutes and appoints Andrew Schinder, Chief Compliance Officer, irrevocably as his true and lawful agent and attorney-in-fact (the “Attorney”), in his name, place and stead, to execute regulato |
|
| October 3, 2024 |
XAIR / Beyond Air, Inc. / Avenue Venture Opportunities Fund, L.P. - SC 13G Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Act of 1934 (Amendment No. )* BEYOND AIR, INC. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 08862L103 (CUSIP Number) September 26, 2024 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant |
|
| October 3, 2024 |
EX-99.2 3 beyondairex99-2.htm EXHIBIT 99.2 Exhibit 99.2 AGREEMENT JOINT FILING OF SCHEDULE 13G Each of the undersigned hereby agrees to file jointly the Schedule 13G to which this Agreement is attached, and any amendments to the Schedule 13G (the “Schedule 13G”) filed with respect to the common stock, par value $0.0001 per share, of Beyond Air, Inc., which may be deemed necessary, pursuant to Regu |
|
| October 2, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): September 27, 2024 Beyond Air, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-38892 47-3812456 (State or Other Jurisdiction of Incorporation) (Commission File Nu |
|
| September 27, 2024 |
Exhibit 10.3 August 16, 2024 Strictly Confidential Steve Lisi Chief Executive Officer and Chairman of the Board Beyond Air, Inc. 900 Stewart Avenue, Suite 301 Garden City, NY 11530 Dear Steve: This letter agreement (this “Agreement”) confirms the understanding with respect to the new engagement by Beyond Air, Inc. (collectively with its subsidiaries and affiliates, the “Company”) of BTIG, LLC (“BT |
|
| September 27, 2024 |
Exhibit 4.2 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR THE SECURITIES LAWS OF ANY STATE OF THE UNITED STATES OR IN ANY OTHER JURISDICTION. NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE MAY BE OFFERED, SOLD OR TRANSFERRED IN THE ABSENCE OF AN EFFECTIVE REGISTR |
|
| September 27, 2024 |
Exhibit 10.1 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”) is dated as of September [ ], 2024 (the “Effective Date”), among Beyond Air, Inc., a Delaware corporation (the “Company”), and each purchaser identified on Exhibit A attached hereto (each a “Purchaser” and, collectively, the “Purchasers”). WHEREAS, the Company and the Purchasers are executing and deliv |
|
| September 27, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): September 26, 2024 Beyond Air, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-38892 47-3812456 (State or Other Jurisdiction of Incorporation) (Commission File Nu |
|
| September 27, 2024 |
Exhibit 10.2 REGISTRATION RIGHTS AGREEMENT This Registration Rights Agreement (this “Agreement”) is made and entered into as of September [ ], 2024, by and between Beyond Air, Inc., a Delaware corporation (the “Company”), and each of the several purchasers signatory hereto (each such purchaser, a “Purchaser” and, collectively, the “Purchasers”). This Agreement is made pursuant to the Securities Pu |
|
| September 27, 2024 |
Exhibit 4.1 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR THE SECURITIES LAWS OF ANY STATE OF THE UNITED STATES OR IN ANY OTHER JURISDICTION. NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE MAY BE OFFERED, SOLD OR TRANSFERRED IN THE ABSENCE OF AN EFFECTIVE REGISTR |
|
| September 27, 2024 |
Exhibit 99.1 Beyond Air Announces $20.6 Million Private Placement Offering Priced At-the-Market Under Nasdaq Rules – Financing strengthens balance sheet and is expected to provide sufficient cash runway through June 2026 – – Retiring $17.5 million in Avenue Capital debt, aided by $11.5 million in new debt from insider-led group; eliminates $12 million in scheduled debt payments through June 2026 – |
|
| August 28, 2024 |
Beyond Air, Inc. 900 Stewart Avenue, Suite 301 Garden City, NY 11530 August 28, 2024 Beyond Air, Inc. 900 Stewart Avenue, Suite 301 Garden City, NY 11530 August 28, 2024 VIA EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Re: Beyond Air, Inc. Registration Statement on Form S-3 Filed August 20, 2024 File No. 333-281667 Request for Acceleration of Effective Date Ladies and Gentlemen: Pursuant to Rule 461 of the |
|
| August 27, 2024 |
August 27, 2024 Steven Lisi Chief Executive Officer Beyond Air, Inc. 900 Stewart Avenue, Suite 301 Garden City, NY 11530 Re: Beyond Air, Inc. Registration Statement on Form S-3 Filed August 20, 2024 File No. 333-281667 Dear Steven Lisi: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for accelerat |
|
| August 20, 2024 |
As filed with the Securities and Exchange Commission on August 20, 2024 As filed with the Securities and Exchange Commission on August 20, 2024 Registration Statement No. |
|
| August 20, 2024 |
Exhibit 107 Calculation of Filing Fee Tables Form S-3 (Form Type) Beyond Air, Inc. |
|
| August 9, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): August 6, 2024 Beyond Air, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-38892 47-3812456 (State or Other Jurisdiction of Incorporation) (Commission File Number |
|
| August 9, 2024 |
Exhibit 99.1 Beyond Air® Reports Fiscal First Quarter 2025 Financial Results and Provides Corporate Update Revenues increased 45% compared to the previous quarter ended March 31, 2024 Optimized LungFit PH device continues to expand footprint and strengthen customer base Amir Avniel, Beyond Air Board member and Chief Business Officer, appointed Chief Executive Officer of NeuroNOS, Beyond Air’s whol |
|
| August 6, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38892 BEYOND AIR, INC. (Exa |
|
| June 27, 2024 |
Exhibit 4.1 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTR |
|
| June 27, 2024 |
Exhibit 10.1 First Amendment to Loan Documents This First Amendment to Loan Documents (this “Amendment”) is entered into as of June 21, 2024, by and among AVENUE CAPITAL MANAGEMENT II, L.P., a Delaware limited partnership (as administrative and collateral agent (in such capacity, “Agent”)), AVENUE VENTURE OPPORTUNITIES FUND, L.P., a Delaware limited partnership (“Avenue”), AVENUE VENTURE OPPORTUNI |
|
| June 27, 2024 |
Exhibit 4.2 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTR |
|
| June 27, 2024 |
Exhibit 99.1 Beyond Air® Reports Fiscal Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update Appointed industry veteran, David Webster, as new Chief Commercial Officer Recently upgraded LungFit PH device expands customer base; revenue growth expected to accelerate each quarter going forward FY 2025 revenue guidance revised to greater than $10 million Implemented capita |
|
| June 27, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): June 21, 2024 Beyond Air, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-38892 47-3812456 (State or Other Jurisdiction of Incorporation) (Commission File Number) |
|
| June 24, 2024 |
List of subsidiaries of Beyond Air, Inc. Exhibit 21.1 Subsidiary Jurisdiction of Incorporation Beyond Air Ltd. Israel Beyond Air Ireland Limited Ireland Beyond Air Australia Pty. Ltd. Australia Beyond Cancer Bermuda Limited Bermuda Beyond Cancer U.S., Inc. Delaware NeuroNos Limited Ireland NeuroNos Israel Limited Israel XAIR Israel Ltd Israel Beyond Cancer Cyprus Limited Cyprus |
|
| June 24, 2024 |
Consulting Agreement, dated as of February 14, 2024, by and between Beyond Air, Inc. and Jeff Myers. Exhibit 10.31 CONSULTANCY AGREEMENT This Consultancy Agreement (the “Agreement”) is entered into on February , 2024, by and between Beyond Air, Inc., a company incorporated in the State of Delaware (the “Company”), and Jeff Myers, M.D., Ph.D. residing 1001 Julia Street, New Orleans, LA 70113 (the “Consultant”). WHEREAS, the Consultant serves as Chief Medical Officer under the terms set forth in hi |
|
| June 24, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE FISCAL YEAR ENDED MARCH 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission file number: 001-38892 BEYOND AIR, INC. |
|
| June 24, 2024 |
Beyond Air, Inc. [Compensation Recoupment] Policy, effective October 2, 2023 Exhibit 97 Beyond Air, Inc. Incentive Compensation Recovery Policy Adopted by the Board of Directors (the “Board”) of Beyond Air, Inc. (the “Company”) on November 20, 2023 The Company is committed to conducting business in accordance with the highest ethical and legal standards, and the Board believes that a culture that emphasizes integrity and accountability is in the best interests of the Compa |
|
| June 18, 2024 |
Other Events, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): June 13, 2024 Beyond Air, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-38892 47-3812456 (State or Other Jurisdiction of Incorporation) (Commission File Number) |
|
| June 18, 2024 |
Exhibit 99.1 Beyond Air® Appoints David Webster as Chief Commercial Officer Mr. Webster brings more than 20 years of executive level experience in the life sciences industry GARDEN CITY, N.Y., June 13, 2024 – Beyond Air, Inc. (NASDAQ: XAIR) (“Beyond Air” or the “Company”), a commercial stage medical device and biopharmaceutical company focused on harnessing the power of endogenous and exogenous ni |
|
| March 22, 2024 |
Exhibit 4.1 COMMON STOCK PURCHASE WARRANT BEYOND AIR, INC. Warrant Shares: Initial Exercise Date: March 22, 2024 THIS COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the date hereof (the “Initial Exe |
|
| March 22, 2024 |
Other Events, Entry into a Material Definitive Agreement, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 20, 2024 BEYOND AIR, INC (Exact name of registrant as specified in its charter) Delaware 001-38892 47-3812456 (State or other jurisdiction (Commission (IRS Employer of incorpora |
|
| March 22, 2024 |
Exhibit 1.1 PLACEMENT AGENCY AGREEMENT March 20, 2024 Roth Capital Partners, LLC 888 San Clemente Drive, Suite 400 Newport Beach, CA 92660 Laidlaw & Company (UK) Ltd. 521 Fifth Avenue, 12th Floor New York, NY 10175 Ladies and Gentlemen: Introduction. Subject to the terms and conditions herein (this “Agreement”), Beyond Air, Inc., a Delaware corporation (the “Company”), hereby agrees to sell up to |
|
| March 22, 2024 |
Exhibit 99.1 Beyond Air® Announces Pricing of $16.0 Million Registered Direct Offering of Common Stock and Warrants March 20, 2024 | 9:02 am EST GARDEN CITY, N.Y., March 20, 2024 — Beyond Air, Inc. (NASDAQ: XAIR) (“Beyond Air” or the “Company”), a commercial stage medical device and biopharmaceutical company focused on harnessing the power of endogenous and exogenous nitric oxide (NO) to improve t |
|
| March 22, 2024 |
Exhibit 10.1 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”) is dated as of , 2024, between Beyond Air, Inc., a Delaware corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively the “Purchasers”). WHEREAS, subject to the terms and conditions set forth in t |
|
| March 22, 2024 |
Filed Pursuant to Rule 424(b)(5) Registration No. 333-262311 PROSPECTUS SUPPLEMENT (To Prospectus dated February 1, 2022) Beyond Air, Inc. 9,638,556 Shares of Common Stock Common Stock Warrants to Purchase 9,638,556 Shares of Common Stock Up to 9,638,556 Shares of Common Stock underlying such Common Stock Warrants We are offering (i) 9,638,556 shares of our common stock, par value $0.001 per share |
|
| March 14, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): March 8, 2024 Beyond Air, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-38892 47-3812456 (State or Other Jurisdiction of Incorporation) (Commission File Number) |
|
| March 7, 2024 |
XAIR / Beyond Air, Inc. / BlackRock Inc. Passive Investment SC 13G 1 us08862l1035030624.txt us08862l1035030624.txt SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No: ) Beyond Air, Inc. - (Name of Issuer) Common Stock - (Title of Class of Securities) 08862L103 - (CUSIP Number) February 29, 2024 - (Date of Event Which Requires Filing of this Statement) Check the appropriate box to d |
|
| March 1, 2024 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 28, 2024 Beyond Air, Inc. (Exact Name of Registrant as Specified in Its Charter) Delaware 001-38892 47-3812456 (State or Other Jurisdiction of Incorporation) (Commission File |
|
| March 1, 2024 |
Exhibit 10.1 AMENDMENT NO. 1 TO SALES AGREEMENT February 28, 2024 Truist Securities, Inc. 3333 Peachtree Road, 11th Floor Atlanta, Georgia 30326 Oppenheimer & Co. Inc. 85 Broad Street New York, New York 10004 Ladies and Gentlemen: Beyond Air, Inc., a Delaware corporation (the “Company”), together with Truist Securities, Inc. (“Truist”) and Oppenheimer & Co. Inc. (“Oppenheimer”), are parties to tha |
|
| March 1, 2024 |
Up to $50,000,000 Beyond Air, Inc. Common Stock Filed Pursuant to Rule 424(b)(5) Registration No. 333-262311 PROSPECTUS SUPPLEMENT (To Prospectus dated February 1, 2022 and Prospectus Supplement dated February 4, 2022) February 28, 2024 Up to $50,000,000 Beyond Air, Inc. Common Stock This prospectus supplement (the “Supplement”) supplements the prospectus supplement (the “Prospectus Supplement”), dated February 4, 2022, providing for the offer |
|
| February 16, 2024 |
Financial Statements and Exhibits, Results of Operations and Financial Condition, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): February 12, 2024 Beyond Air, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-38892 47-3812456 (State or Other Jurisdiction of Incorporation) (Commission File Num |
|
| February 16, 2024 |
Exhibit 99.1 Beyond Air® Reports Financial Results for Third Quarter of Fiscal Year 2024 Commercial demand for LungFit® PH increasing; manufacturing of upgraded devices is ramping up to meet growing demand PMA supplement for the expansion of LungFit PH label to include cardiac surgery accepted for filing and under substantive review by the FDA U.S. pilot trial of LungFit® PRO to treat viral commun |
|
| February 14, 2024 |
XAIR / Beyond Air, Inc. / Mosseri Marlio Charles - PRIMARY DOCUMENT Passive Investment SC 13G/A 1 charlesmosserimarlio13g-a.htm PRIMARY DOCUMENT UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A (Amendment No. 4)* UNDER THE SECURITIES EXCHANGE ACT OF 1934 Beyond Air, Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 08862L103 (CUSIP Number) December 31, 2023 (Date of Event Which Requires Filing of this |
|
| February 12, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended December 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38892 BEYOND AIR, INC. |
|
| February 8, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Definitive Proxy State |
|
| January 29, 2024 |
XAIR / Beyond Air, Inc. / BlackRock Inc. Passive Investment us08862l1035012924.txt SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No: ) Beyond Air, Inc. - (Name of Issuer) Common Stock - (Title of Class of Securities) 08862L103 - (CUSIP Number) December 31, 2023 - (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to wh |
|
| January 26, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Definitive Proxy State |
|
| December 20, 2023 |
As filed with the Securities and Exchange Commission on December 20, 2023 As filed with the Securities and Exchange Commission on December 20, 2023 Registration No. |
|
| December 20, 2023 |
Form of Restricted Stock Unit Agreement (Inducement Restricted Stock Unit Award). Exhibit 10.3 BEYOND AIR, INC. RESTRICTED STOCK UNIT GRANT NOTICE (INDUCEMENT AWARD) Beyond Air, Inc. (the “Company”) hereby awards to Participant a Restricted Stock Unit Award for the number of shares of the Company’s Common Stock (“Restricted Stock Units”) set forth below (the “Award”). The Restricted Stock Units are granted to the Participant in connection with the Participant’s entering into em |
|
| December 20, 2023 |
Form of Stock Option Agreement (Inducement Stock Option Award). Exhibit 10.2 Stock Option Inducement Agreement This Stock Option Inducement Agreement (this “Agreement”) is made and entered into as of [DATE] by and between BEYOND AIR, INC., a Delaware corporation (the “Company”) and [NAME] (the “Participant”). Grant Date: Exercise Price per Share: Number of Option Shares: Expiration Date: 1. Grant of Option. 1.1 Grant; Type of Option. The Company desires to emp |
|
| December 20, 2023 |
Exhibit 107 Calculation of Filing Fee Table Form S-8 (Form Type) Beyond Air, Inc. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered(1) Proposed Maximum Offering Price Per Unit Proposed Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Equity Common Stock, par value |
|
| November 17, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): November 13, 2023 Beyond Air, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-38892 47-3812456 (State or Other Jurisdiction of Incorporation) (Commission File Num |
|
| November 17, 2023 |
Exhibit 99.1 Beyond Air® Reports Financial Results for Second Quarter of Fiscal Year 2024 Provides fiscal year 2025 revenue guidance of $12 - $16 million US pilot trial of LungFit® PRO to treat viral community acquired pneumonia (VCAP) underway with data expected mid-calendar 2024 Beyond Cancer presents positive first-in-human data for intratumoral administration of ultra-high concentration nitric |
|
| November 13, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38892 BEYOND AIR, INC. |
|
| September 7, 2023 |
Exhibit 99.1 Beyond Air® and Getz Healthcare Enter Strategic Collaboration to Commercialize LungFit PH in Asia-Pacific Region Partnership provides access to hospitals in key Asia-Pacific countries Getz Healthcare will make a payment to Beyond Air upon receipt of CE Mark Beyond Air will receive royalty payments based on net sales Garden City, NY, September 7, 2023 – Beyond Air, Inc. (NASDAQ: XAIR) |
|
| September 7, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): September 7, 2023 Beyond Air, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-38892 47-3812456 (State or Other Jurisdiction of Incorporation) (Commission File Num |
|
| August 17, 2023 |
United States securities and exchange commission logo August 16, 2023 Steven Lisi Chairman and Chief Executive Officer Beyond Air, Inc. |
|
| August 17, 2023 |
Beyond Air, Inc. 900 Stewart Avenue, Suite 301 Garden City, NY 11530 August 17, 2023 Beyond Air, Inc. 900 Stewart Avenue, Suite 301 Garden City, NY 11530 August 17, 2023 VIA EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Re: Beyond Air, Inc. Registration Statement on Form S-3 Filed August 11, 2023 File No. 333-273942 Request for Acceleration of Effective Date Ladies and Gentlemen: Pursuant to Rule 461 of the |
|
| August 15, 2023 |
Exhibit 99.1 Beyond Air® Reports Financial Results for First Quarter of Fiscal Year 2024 Reported commercial sales for LungFit® PH for the treatment of term and near-term neonates with hypoxic respiratory failure Currently have in excess of $1 million in annual commercial LungFit PH contracts Secured up to $40 million in debt financing from Avenue Capital Reached agreement with FDA to run a U.S. c |
|
| August 15, 2023 |
Results of Operations and Financial Condition, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): August 10, 2023 Beyond Air, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-38892 47-3812456 (State or Other Jurisdiction of Incorporation) (Commission File Numbe |
|
| August 11, 2023 |
As filed with the Securities and Exchange Commission on August 11, 2023 As filed with the Securities and Exchange Commission on August 11, 2023 Registration Statement No. |
|
| August 11, 2023 |
Exhibit 107 Calculation of Filing Fee Tables Form S-3 (Form Type) Beyond Air, Inc. |
|
| August 10, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38892 BEYOND AIR, INC. (Exa |
|
| June 23, 2023 |
Results of Operations and Financial Condition, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): June 22, 2023 Beyond Air, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-38892 47-3812456 (State or Other Jurisdiction of Incorporation) (Commission File Number) |
|
| June 23, 2023 |
Exhibit 99.1 Beyond Air® Reports Financial Results for Fourth Quarter and Fiscal Year-End 2023 Successfully completed phase 1 of U.S. commercial launch, with multiple hospitals contracted, and have initiated phase 2 of launch for LungFit® PH for the treatment of term and near-term neonates with hypoxic respiratory failure Presented positive preclinical data for ultra-high concentration nitric oxid |
|
| June 22, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE FISCAL YEAR ENDED MARCH 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission file number: 001-38892 BEYOND AIR, INC. |
|
| June 22, 2023 |
Employment Agreement, dated as of March 27, 2023, by and between Beyond Air, Inc. and Jeff Myers. Exhibit 10.29 EMPLOYMENT AGREEMENT EMPLOYMENT AGREEMENT (“Agreement”) is effective on March 27th, 2023 between Beyond Air, Inc. (the “Company”), a Delaware Company, and Jeff L. Myers, M.D., Ph.D. (the “Employee”), residing at 1001 Julia Street, New Orleans, LA 70113. Recital: The parties desire to enter into this Agreement so as to provide for the employment of the Employee by the Company and for |
|
| June 22, 2023 |
List of subsidiaries of Beyond Air, Inc. Exhibit 21.1 Subsidiary Jurisdiction of Incorporation Beyond Air Ltd. Israel Beyond Air Ireland Limited Ireland Beyond Air Australia Pty. Ltd. Australia Beyond Cancer Bermuda Limited Bermuda Beyond Cancer U.S., Inc. Delaware XAIR Israel Ltd Israel Beyond Cancer Cyprus Limited Cyprus |
|
| June 20, 2023 |
Exhibit 4.2 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTR |
|
| June 20, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): June 15, 2023 Beyond Air, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-38892 47-3812456 (State or Other Jurisdiction of Incorporation) (Commission File Number) |
|
| June 20, 2023 |
Exhibit 10.1 LOAN AND SECURITY AGREEMENT Dated as of June 15, 2023 among BEYOND AIR, INC., a Delaware corporation, as “Borrower”, BEYOND AIR LTD., an Israeli private company, company # 514609387 as a “Israeli Guarantor” or “Beyond Israel” and AVENUE CAPITAL MANAGEMENT II, L.P., a Delaware limited partnership (as administrative agent and collateral agent (in such capacity “Agent”) and AVENUE VENTUR |
|
| June 20, 2023 |
Exhibit 4.1 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTR |
|
| June 20, 2023 |
Exhibit 99.1 Beyond Air® Secures up to $40 Million Debt Financing Funding to support the commercialization of LungFit® PH and advance the clinical development of high concentration nitric oxide treatment using Beyond Air’s revolutionary LungFit platform technology GARDEN CITY, N.Y., June 15, 2023 – Beyond Air, Inc. (NASDAQ: XAIR) (“Beyond Air” or the “Company”), a commercial stage medical device a |
|
| June 20, 2023 |
Exhibit 10.2 SUPPLEMENT to the Loan and Security Agreement dated as of June 15, 2023 among BEYOND AIR, INC. (“Borrower”) and AVENUE CAPITAL MANAGEMENT II, L.P., a Delaware limited partnership, as administrative agent and collateral agent (in such capacity “Agent”) and AVENUE VENTURE OPPORTUNITIES FUND, L.P., a Delaware limited partnership (“Avenue”), as a lender and AVENUE VENTURE OPPORTUNITIES FU |
|
| March 24, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): March 23, 2023 Beyond Air, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-38892 47-3812456 (State or Other Jurisdiction of Incorporation) (Commission File Number |
|
| March 23, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): March 23, 2023 Beyond Air, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-38892 47-3812456 (State or Other Jurisdiction of Incorporation) (Commission File Number |
|
| March 23, 2023 |
Exhibit 99.1 Beyond Air® Appoints Jeff Myers, M.D. Ph.D. as Chief Medical Officer Dr. Myers brings extensive executive experience leading the development of clinical programs through US and global regulatory approval Garden City, NY, March 23, 2023 – Beyond Air, Inc. (NASDAQ: XAIR) (“Beyond Air” or the “Company”), a commercial stage medical device and biopharmaceutical company focused on developin |
|
| March 13, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): March 9, 2023 Beyond Air, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-38892 47-3812456 (State or Other Jurisdiction of Incorporation) (Commission File Number) |
|
| February 17, 2023 |
As filed with the Securities and Exchange Commission on February 17, 2023 As filed with the Securities and Exchange Commission on February 17, 2023 Registration No. |
|
| February 17, 2023 |
Form of Stock Option Agreement (Inducement Grant). Exhibit 10.2 Stock Option Inducement Agreement This Stock Option Inducement Agreement (this “Agreement”) is made and entered into as of [DATE] by and between BEYOND AIR, INC., a Delaware corporation (the “Company”) and [NAME] (the “Participant”). Grant Date: Exercise Price per Share: Number of Option Shares: Expiration Date: 1. Grant of Option. 1.1 Grant; Type of Option. The Company desires to emp |
|
| February 17, 2023 |
Exhibit 107 Calculation of Filing Fee Table Form S-8 (Form Type) Beyond Air, Inc. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered(1) Proposed Maximum Offering Price Per Unit Proposed Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Equity Common Stock, par value |
|
| February 14, 2023 |
XAIR / Beyond Air Inc / Mosseri Marlio Charles - SC 13G/A Passive Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 Beyond Air, Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 08862L103 (CUSIP Number) December 31, 2022 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedule |
|
| February 13, 2023 |
Exhibit 99.1 Beyond Air® Reports Financial Results for the Third Quarter of Fiscal Year 2023 U.S. commercial launch continues for LungFit® PH for the treatment of term and near-term neonates with hypoxic respiratory failure Presented positive in vivo combination data with anti-PD1 that support the potential of the Company’s novel gaseous ultra-high concentration nitric oxide (UNO) therapy to treat |
|
| February 13, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): February 9, 2023 Beyond Air, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-38892 47-3812456 (State or Other Jurisdiction of Incorporation) (Commission File Numb |
|
| February 10, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended December 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38892 BEYOND AIR, INC. |
|
| January 31, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Definitive Proxy State |
|
| January 27, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Definitive Proxy State |
|
| November 14, 2022 |
Results of Operations and Financial Condition, Other Events, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): November 8, 2022 Beyond Air, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-38892 47-3812456 (State or Other Jurisdiction of Incorporation) (Commission File Numb |
|
| November 14, 2022 |
Exhibit 99.1 Beyond Air? Reports Financial Results for the Second Quarter of Fiscal Year 2023 Commercial launch underway for LungFit? PH for the treatment of term and near-term neonates with hypoxic respiratory failure, which received FDA approval on June 28, 2022 Presented favorable safety, tolerability, and efficacy results from the pilot study of at-home LungFit? GO for nontuberculous mycobacte |
|
| November 14, 2022 |
Exhibit 99.2 Beyond Cancer? Presents Promising New In Vivo Data Showing Ultra-High Concentration Nitric Oxide Therapy (UNO) in Combination with Anti-PD-1 During the Society for Immunotherapy of Cancer (SITC) 2022 Annual Meeting Data showing UNO in combination with anti-PD-1 treatment leads to significantly higher tumor regression rates UNO in combination with anti-PD-1 treatment results in a highe |
|
| November 8, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2022 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38892 BEYOND AIR, INC. |
|
| October 20, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): October 20, 2022 Beyond Air, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-38892 47-3812456 (State or Other Jurisdiction of Incorporation) (Commission File Numb |
|
| October 20, 2022 |
Exhibit 99.1 Beyond Air? Announces Positive Data from At-Home Pilot Study in Patients with Refractory NTM Lung Infection Treated with (NO) using the LungFit? GO at the CHEST Annual Meeting 2022 ? Data show favorable safety, tolerability, and efficacy results ? ? All patients titrated to 250 ppm NO with no patients needing to reduce concentration ? ? All patients demonstrated ability to self-admini |
|
| October 7, 2022 |
Financial Statements and Exhibits, Changes in Registrant's Certifying Accountant UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): October 6, 2022 Beyond Air, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-38892 47-3812456 (State or Other Jurisdiction of Incorporation) (Commission File Numbe |
|
| October 7, 2022 |
Letter from Friedman LLP to the Securities and Exchange Commission, dated October 6, 2022 Exhibit 16.1 October 6, 2022 Securities and Exchange Commission 100 F Street, NE Washington, D.C. 20549 Re: Beyond Air, Inc. Commission File Number 001-38892 Commissioners: We have read the statements made by Beyond Air, Inc. under Item 4.01 of its Form 8-K dated October 6, 2022. We agree with the statements concerning our firm in such Form 8-K; we are not in a position to agree or disagree with o |
|
| September 22, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION September 22, 2022 ORDER GRANTING CONFIDENTIAL TREATMENT UNDER THE SECURITIES EXCHANGE ACT OF 1934 Beyond Air, Inc. |
|
| August 23, 2022 |
Exhibit 99.1 Beyond Air? Affiliate Beyond Cancer? Doses Initial Patient in First-in-Human Phase 1 Study of Ultra- High Concentration Nitric Oxide Therapy at Tel Aviv Sourasky Medical Center (Ichilov) GARDEN CITY, N.Y. and HAMILTON, Bermuda, Aug. 23, 2022 ? Beyond Cancer, Ltd., an affiliate of Beyond Air, Inc. (NASDAQ: XAIR) that is focused on developing ultra-high concentration nitric oxide (UNO) |
|
| August 23, 2022 |
Other Events, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): August 23, 2022 Beyond Air, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-38892 47-3812456 (State or Other Jurisdiction of Incorporation) (Commission File Numbe |
|
| August 15, 2022 |
Results of Operations and Financial Condition, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): August 11, 2022 Beyond Air, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-38892 47-3812456 (State or Other Jurisdiction of Incorporation) (Commission File Numbe |
|
| August 15, 2022 |
Exhibit 99.1 Beyond Air? Reports Financial Results for the First Quarter of Fiscal Year 2023 Initiated U.S. commercial launch of LungFit? PH for the treatment of term and near-term neonates with hypoxic respiratory failure, which received FDA approval on June 28, 2022 Will present data from the pilot study of at-home LungFit? GO for nontuberculous mycobacterial lung infection at the American Colle |
|
| August 11, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38892 BEYOND AIR, INC. (Exa |
|
| July 5, 2022 |
Exhibit 10.1 April 24, 2020 via email Michael Gaul 4975 E. Lake Road Sheffield Lake, OH 44054 Re: Employment as Senior VP, Operations Dear Mr. Gaul: We are pleased to offer you a position as Senior VP, Operations on the terms set forth below. 1. Job title Your title will be Senior VP, Operations and you will report to Steve Lisi. The reporting structure may change from time to time, at the discret |
|
| July 5, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): June 28, 2022 Beyond Air, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-38892 47-3812456 (State or Other Jurisdiction of Incorporation) (Commission File Number) |
|
| June 30, 2022 |
Exhibit 99.1 Beyond Air? Reports Financial Results for Fourth Fiscal Quarter and Year-End 2022 LungFit? PH received FDA approval for the treatment of term and near-term neonates with hypoxic respiratory failure on June 28, 2022 and the first phase of U.S. commercial launch has begun Presented positive data for high-concentration nitric oxide (NO) with LungFit? PRO in hospitalized patients with com |
|
| June 30, 2022 |
Exhibit 99.2 Beyond Air?s LungFit? PH Receives FDA Approval to Treat Term and Near-Term Neonates with Hypoxic Respiratory Failure First and only nitric oxide generator and delivery system indicated for the treatment of term and near-term neonates with hypoxic respiratory failure that uses ambient air to provide unlimited, on-demand nitric oxide Eliminates the need for traditional nitric oxide tank |
|
| June 30, 2022 |
Other Events, Results of Operations and Financial Condition, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): June 28, 2022 Beyond Air, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-38892 47-3812456 (State or Other Jurisdiction of Incorporation) (Commission File Number) |
|
| June 29, 2022 |
List of subsidiaries of Beyond Air, Inc. Exhibit 21.1 Subsidiary Jurisdiction of Incorporation Beyond Air Ltd. Israel Beyond Air Ireland Limited Ireland Beyond Air Australia Pty. Ltd. Australia Beyond Cancer Bermuda Limited Bermuda Beyond Cancer U.S., Inc. Delaware XAIR Israel Ltd Israel Beyond Cancer Cyprus Limited Cyprus |
|
| June 29, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-K (Mark One) ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE FISCAL YEAR ENDED MARCH 31, 2022 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission file number: 001-38892 BEYOND AIR, INC. |
|
| March 4, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): March 3, 2022 Beyond Air, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-38892 47-3812456 (State or Other Jurisdiction of Incorporation) (Commission File Number) |
|
| February 14, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): February 10, 2022 Beyond Air, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-38892 47-3812456 (State or Other Jurisdiction of Incorporation) (Commission File Num |
|
| February 14, 2022 |
Exhibit 99.1 Beyond Air? Reports Financial Results for the Third Quarter of Fiscal Year 2022 LungFit? PH premarket approval (PMA) submission under active review by U.S. FDA; approval and commercial launch anticipated in the first half of calendar year 2022 along with European CE Mark Raised $30 million for oncology affiliate Beyond Cancer?, Beyond Air maintained an 80% equity ownership; first in h |
|
| February 11, 2022 |
XAIR / Beyond Air Inc / Flynn James E Passive Investment SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b)(c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(b) (Amendment No. |
|
| February 10, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended December 31, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38892 BEYOND AIR, INC. |
|
| February 9, 2022 |
XAIR / Beyond Air Inc / Mosseri Marlio Charles - SC 13G/A Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Amendment No. 2 UNDER THE SECURITIES EXCHANGE ACT OF 1934 Beyond Air, Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 08862L103 (CUSIP Number) December 31, 2021 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule p |
|
| February 4, 2022 |
Exhibit 1.1 Beyond Air, Inc. $50,000,000 COMMON STOCK SALES AGREEMENT February 4, 2022 Truist Securities, Inc. 3333 Peachtree Road, 11th Floor Atlanta, Georgia 30326 Oppenheimer & Co. Inc. 85 Broad Street New York, New York 10004 Ladies and Gentlemen: Beyond Air, Inc., a Delaware corporation (the ?Company?), Truist Securities, Inc. (?Truist?), as sales agent, and Oppenheimer & Co. Inc. (?Oppenheim |
